9/16/2021 7:05:24 AM
Sutro Biopharma Names Nicole Chieffo VP Of Clinical Operations And Werner Rubas VP Of Preclinical Development
8/18/2021 7:13:46 AM
Sutro Biopharma Reports STRO-002 FDA Fast Track Designation For Patients With Advanced Ovarian Cancer
8/9/2021 7:38:15 AM
Sutro Biopharma Q2 Net Loss $6.1 Mln Vs. Net Profit $29.9 Mln Last Year
5/7/2021 7:49:34 AM
Sutro Biopharma Q1 Loss Per Share $0.66 Vs Loss Per Share $0.84 Last Year
4/15/2021 7:26:27 AM
Sutro Biopharma Earns$15 Mln Milestone Payment From Cytokine Derivatives Collaboration With Merck
1/21/2021 7:11:50 AM
Sutro Biopharma : First Patient Dosed In Dose-Expansion Study Of STRO-002 In Patients With Ovarian Cancer
12/8/2020 9:44:55 PM
Sutro Biopharma Prices Public Offering Of 6 Mln Shares At $21.00/shr
12/7/2020 4:01:46 PM
Sutro Biopharma Announces Proposed Public Offering Of 5 Mln Shares Of Common Stock
12/7/2020 10:09:57 AM
Sutro Biopharma Presents Data From Ongoing Phase 1 Dose-Escalation Study For STRO-001
8/25/2020 7:19:25 AM
Sutro Biopharma Achieves Clinical Supply Milestone From Merck KGaA
6/9/2020 7:09:41 AM
Sutro Biopharma To Present New Preclinical Data On STRO-002 Antibody-Drug Conjugate At AACR On June 22